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Abstract
Background: Implementation of Professional Pharmacy Services (PPSs) requires a demonstration of the service’s
impact (efficacy) and its effectiveness. Several systematic reviews and randomised controlled trials (RCT) have shown
the efficacy of PPSs in patient’s outcomes in community pharmacy. There is, however, a need to determine the
level of evidence on the effectiveness of PPSs in daily practice by means of pragmatic trials.
To identify and analyse pragmatic RCTs that measure the effectiveness of PPSs in clinical, economic and humanistic
outcomes in the community pharmacy setting.
Methods: A systematic search was undertaken in MEDLINE, EMBASE, the Cochrane Library and SCIELO. The search
was performed on January 31, 2020. Papers were assessed against the following inclusion criteria (1) The
intervention could be defined as a PPS; (2) Undertaken in a community pharmacy setting; (3) Was an original paper;
(4) Reported quantitative measures of at least one health outcome indicator (ECHO model); (5) The design was
considered as a pragmatic RCT, that is, it fulfilled 3 predefined attributes. External validity was analyzed with PRECIS-
2 tool.
Results: The search strategy retrieved 1,587 papers. A total of 12 pragmatic RCTs assessing 5 different types of PPSs
were included. Nine out of the 12 papers showed positive statistically significant differences in one or more of the
primary outcomes (clinical, economic or humanistic) that could be associated with the following PPS: Smoking
cessation, Dispensing/Adherence service, Independent prescribing and MTM. No paper reported on cost-
effectiveness outcomes.
Conclusions: There is limited available evidence on the effectiveness of community-based PPS. Pragmatic RCTs to
evaluate clinical, humanistic and economic outcomes of PPS are needed.
Keywords: Naturalistic, Comparative effectiveness research, Pragmatic clinical trials, Pharmaceutical care,
Community pharmacy services, Clinical pharmacy services, Professional pharmacy services, Community pharmacy
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Background
The pharmacy profession is constantly evolving from the
traditional role of dispensing medicines towards patient-
centred and collaborative care [1, 2], as it adapts to the
demands and needs of patients [3, 4]. This practice
change [5], internationally acknowledged and supported
by professional organisations [6, 7], involves expanding
the roles of pharmacists, by increasing their responsibil-
ity for the outcomes of medication therapy [8]. In com-
munity pharmacy, the change is operationalized through
the implementation of professional pharmacy services
(PPSs). A professional pharmacy service is defined as
“an action or set of actions undertaken in or organised by
a pharmacy, delivered by a pharmacist or other health
practitioner, who applies their specialized health know-
ledge personally or via an intermediary, with a patient/
client, population or other health professional, to opti-
mise the process of care, with the aim to improve health
outcomes and the value of health care [9].”
In many countries PPSs are not integrated into daily
practice due to a variety of factors. The main barriers are
lack of evidence, lack of government support and/or no
remuneration for service provision. However, the imple-
mentation process in various countries is at different
phases and has followed different paths [10–12]. In some
countries [12, 13] such as Australia, the United States of
America (USA), Canada and the United Kingdom (UK),
community pharmacists obtain reimbursement for provid-
ing these patient oriented services [2]. Most services are
reimbursed by governments using a fee for service ap-
proach [14–17]. Implementation of reimbursed PPS nor-
mally requires a previous demonstration of the service’s
impact (efficacy) and its effectiveness by means of high-
quality research. However, translating these research find-
ings into practice has been challenging [18, 19]. It is
widely accepted that randomised control trials (RCTs) of
various types are the appropriate research design to evalu-
ate the efficacy of services while effectiveness should be
assessed by means of pragmatic or naturalistic trials [20].
Generally, explanatory RCTs tend to maximize the accur-
acy of the results (internal validity) at the expense of exter-
nal validity (the ability for a result to be applied or used in
a particular situation) [21]. The term pragmatic is used for
trials that test the effectiveness of the intervention in many
clinical practice settings (e.g., inpatient hospitals, emer-
gency departments) [11, 22–24] maximizing applicability
and generalisability [25–27] (high external validity) of
their results. Observational designs are also used to assess
effectiveness [28, 29].
Several RCTs and systematic reviews have reported
the clinical, economic and humanistic outcomes of PPSs
in community pharmacy [30–41], although further re-
search may be needed to determine whether these ser-
vices can improve health-related quality of life and
reduce healthcare costs [42]. Most of the studies re-
ported in the literature have used an explanatory RCT
design, which result in low external validity with conse-
quent limitations associated with the generalisation of
results [43–46]. Results from pragmatic trials may better
meet the needs of stakeholders, healthcare professionals,
payers [47–49] and patients [21]. As a result, there has
been numerous calls to generate a high level of evidence
on the clinical, economic and humanistic effectiveness of
PPSs in daily practice by means of pragmatic trials [50–
53]. It is, however, not easy, to differentiate between an
explanatory and a pragmatic trial. Most trials seem to in-
clude both aspects, acknowledging the notion that ex-
planatory and pragmatic exist in a continuum [54–57].
The PRECIS-2 tool was developed and validated to allo-
cate research designs into this continuum. This tool con-
sists of 9 domains scored from 1 (very explanatory) to 5
(very pragmatic). The domains are: eligibility, recruit-
ment, setting, organisation, flexibility (delivery), flexibil-
ity (adherence), follow-up, primary outcome, and
primary analysis. The main limitation of the PRECIS- 2
tool is that there may be interrater differences when ap-
plying each criterion. However, it provides explicit cri-
teria that enhances discussion and eventual consensus
[58, 59].The PRECIS-2 tool has shown a modest dis-
criminatory validity [60].
This study aims to systematically review the literature
to identify and analyse randomised controlled pragmatic
trials that measure the effectiveness of the PPSs in the
community pharmacy setting.
Methods
A systematic search was undertaken in MEDLINE,
EMBASE, the Cochrane Library and SCIELO, following
PRISMA guidelines [61].
Search strategy
For the search performed in MEDLINE/PubMed the fol-
lowing Mesh terms and key words were used:“Outcome
Assessment (Health Care)”[Mesh] OR (pragmatic[All
Fields] OR (naturalistic[All Fields])))) OR (“Comparative
Effectiveness Research”[Mesh] OR “Pragmatic Clinical
Trials as Topic”[Mesh] OR “Pragmatic Clinical Trial”
[Publication Type]))) AND (“pharmaceutical care”[tiab]
OR “medication review”[tiab] OR “Community Phar-
macy Services”[Mesh] OR “Drug Utilization Review”[-
Mesh] OR “Medication Therapy Management”[Mesh]
OR “clinical pharmacy service”[All Fields] OR “pharma-
cists”[MeSH Terms]). Filters: published in the last 10
years. The search strategies used in the other databases
are included in Appendix. The search was performed by
three of the authors (MAG, LSB and RVD) and the last
update was made on January 31, 2020.
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Selection criteria
The following inclusion criteria were used for the selec-
tion process of papers: (1) The intervention assessed
could be defined as a PPS according to Moullin’s defin-
ition [9]; (2) The intervention assessed was performed in
the community pharmacy setting; (3) Was an original
paper; (4) The trial reported quantitative measures of at
least one health outcome indicator (ECHO model) [62];
(5) The study design was considered as a pragmatic
RCT, that is, it fulfilled 3 of the 4 following key attri-
butes [63, 64]: (a) analyzed the effectiveness of an inter-
vention, (b) included more than 200 patients in each
arm, (c) was undertaken in routine health care, (d) used
broad eligibility criteria. Only articles in English and
Spanish languages were included.
Data collection and analysis
Duplicated records were removed using Endnote©. The
selection process was undertaken by the same three au-
thors (MAG, LSB and RVD). Two independent re-
searchers (RVD, MAG) reviewed the literature; and
disagreements were resolved with a third reviewer (LSB).
In addition, a manual search was performed for refer-
ences not identified in the search through the references
list of the retrieved papers. Abstracts were screened and
excluded if they did not meet the inclusion criteria. Ab-
stracts with insufficient information were assessed in full
text. After excluding at the abstract level, the complete
text of the remaining references was assessed against the
same selection criteria.
The data-extraction form, after being piloted with a
sample of three papers, included:
a) Degree of pragmatism of the studies. To further
characterize the degree of pragmatism of the finally
included papers, the PRECIS-2 tool was used [65].
Three authors (MAG, LSB and RVD) rated the
degree of pragmatism, scoring independently each
trial/study on each of the 9 domains of the PRECIS-
2. After the independent assessment there were
minor differences which were resolved through a
moderation-consensus approach.
b) Internal validity was analyzed following the Centre
for Reviews and Dissemination’s guidance for
undertaking reviews in health care. The following
methodological aspects were selected to assess
quality of the papers for this review; measure of
variability, baseline comparability, contamination
risk and blinded assessment [59].
c) External validity was analyzed with the PRECIS- 2
tool [65].
d) Description of general characteristics of included
papers: type of PPS (interventions were categorized
according to a hierarchical model [66], author,
country, publication year, number of patients,
duration, objectives, design/ method, patient
inclusion/exclusion criteria and outcomes
indicators).
e) Description of the PPS components and summary
of the clinical, economic or humanistic outcomes.






The search strategy retrieved 1556 papers and 31 add-
itional papers were identified from the manual search
from references of the included papers. After removing
duplicates, a total of 1563 references remained. During
the screening of abstracts, 1468 articles were excluded.
Ninety-five papers in full text were assessed, of which 83
were excluded because they did not meet the selection
criteria. Finally (Fig. 1), a total of 12 pragmatic RCTs
were included [49, 51, 67–76].
Studies description
Of the 12 studies identified as pragmatic, three were
cluster randomised controlled trials (cRCT) [49, 51, 72]
while the other nine were RCTs [67–71, 73–76].The
duration of the studies varied between three [49, 67, 72,
76] and 14months [68] with a mean length of 6.4
months (SD = 3.6). The sample size varied from 65 [70]
to 6987 patients [49]. The mean number of patients in-
cluded in the studies was 1029.75 (SD = 1892.0) with a
median of 541.0.
The mean number of pharmacists per study delivering
the intervention was 55.2 (SD = 37.5) although in one
paper only one pharmacist was involved [76]. In six of
the studies pharmacists were reimbursed for providing
PPS [51, 68–70, 72, 74]. In seven of the 12 studies there
was training for the intervention [49, 51, 69–73], either
face-to-face, on-line or both, with a duration of between
six and 48 h. In the remaining five studies [67, 68, 74–
76] no training was delivered as the pharmacies or
pharmcists were already accredited for PPS provision.
Degree of pragmatism and study quality
All eligible papers scored over 50% on the PRECIS-2
scale, which reinforced their external validity and were
considered pragmatic. The scores ranged from 24.0/45
to 41.5/45 (Fig. 2). The highest value for each PRECIS-2
domain were obtained for Setting (average 4.6/5) and
Primary analysis (average 3.8/5) while the lowest value
was found in Organisation criteria (average 3.0/5). The
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complete assesesment of PRECIS-2 tool is available in
the Additional file 1.
With respect to internal validity, nine papers stated
confidence intervals or size effects for their main out-
come indicators [49, 67, 68, 71–76]. Only three papers
presented baseline differences between groups [70, 71,
75] and these used a statistical technique to adjust for
such differences. In six out of the nine non cluster RCT,
the authors recognized contamination risk between
groups [68, 69, 71, 73–75]. Only one RCT used a
blinded assessor [71]. Nine out of 12 analyses were based
on intention to treat (ITT) [51, 67, 68, 70–75] whereas
the remaining three were per protocol [49, 69, 76].
Type of PPSs
The PPSs reported were classified as eight different types
[66]: Dispensing/Adherence service [71, 72]; Smoking
cessation service [49]; New Medicine Service (NMS)
[68]; Independent prescribing [74]; Medication Therapy
Management (MTM) [67, 70, 76]; Clinical Medication
Reviews (CMR) [69, 75]; Disease State Management
(DSM) [51] and Pharmaceutical Care (PC) [73]. Since
CMR [69, 75], DSM [51], PC [73] and MTM services
[67, 70, 76] included a care plan, implying a continuous
intervention and evaluation of patients’ outcomes, they
were recategorized as MTM [77]. Therefore, five differ-
ent types of PPSs were finally evaluated.
Pharmacists delivered the service by means of an indi-
vidualized face to face consultation with patients [49, 51,
69–75], telephone contact [68, 76], or review of patient’s
records without patient contact [67].
Four out of the 12 studies [49, 51, 72, 73] reported pa-
tients’ loss to follow up rates higher than 15%. The main
causes of dropouts were hospitalization [73], inability to
contact [75, 76], not giving informed consent [75], lost
to follow up [49, 51, 67, 70, 71, 73], death [73, 75], not
having time for the study and for no specific reason [67,
68, 74].
Further descriptions of the general characteristics of
included articles are provided in Table 1.
Clinical, economic or humanistic outcomes of the
interventions
Nine out of the 12 studies showed positive statistically
significant differences in a clinical primary outcome that
could be associated with four PPS: Smoking cessation
[49], Dispensing/Adherence service [71], Independent
prescribing [74] and MTM [51, 67, 69, 70, 73, 76]. The
other three studies only achieved significant statistical
improvements in subgroup analysis [75], secondary out-
comes [72] and/or process indicators [68]. Description
of the interventions and detailed clinical, economic or
humanistic primary outcomes of papers included are
provided in Table 2.
Clinical outcomes
Provision of specific PPSs achieved a statistically signifi-
cant better control of several clinical outcome indicators:
Independent prescribing improved blood pressure [74],
Adherence service improved blood pressure [72], Smok-
ing cessation improved abstinence from tobacco [49]
and MTM improved pulmonary exacerbations [73],
Fig. 1 Flow diagram of the screened, assessed for eligibility, included and excluded papers according to PRISMA
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Fig. 2 Assessment of pragmatic degree of trials using PRECIS-2 tool. Image shows PRECIS-2 wheels for PPS according to the degree of
pragmatism: author; PPS: PRECIS-2 score out of 45. 1. Eligibility, 2. Recruitment, 3.Setting, 4.Organisation, 5. Flexibility (delivery), 6. Flexibility
(adherence), 7. Follow-up, 8. Primary outcome, 9. Primary analysis
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Table 1 Description of key general characteristics of included papers
Author / PPS/Country/






n = 573; IG (n = 286) and CG
(n = 287)
To evaluate the effect of pharmacist case finding and
intervention program on estimated cardiovascular (CV)
risk in patients with diabetes.
Primary:
Difference and change in estimated CV risk (validated
risk-assessment equation) between IG and CG.
Secondary
Differences between groups in changes of: HbA1c, LDL
cholesterol levels, blood pressure and tobacco cessation,
medication use and dose changes, lifestyle habits and CV




n = 570; IG (n = 292) and CG
(n = 278)
To test the feasibility, effectiveness and sustainability of
an asthma service.
Primary:
Asthma control (validated assessment equation- ACQ-),




n = 6987; IG (Group A (n =
3588) and Group B (n =
3399))
To evaluate the effectiveness of two models of smoking
cessation that included nicotine replacement therapy
(NRT).
Primary:





n = 504; IG (n = 251) and CG
(n = 253)
To examine the effectiveness of the NMS in people
starting a new medicine for a long-term condition.
Primary:
Adherence (validated assessment equation), health status
(quality of life), medicines understanding and National




n = 512; IG (n = 248) and CG
(n = 264)
To determine whether a medication review followed by a
pharmaceutical care plan decreases potential DRPs and
pharmaceutical care issues (PCIs), along with a positive
effect on cardiovascular risk factors and safety parameters
for elderly polypharmacy patients with a cardiovascular
disorder.
Primary:
Resolved DRPs and PCIs.
Secondary:
Differences in clinical and lab values
[70] Planas
MTM
United States/2012/ 9 months
n = 65; IG (n = 38) and CG
(n = 27)
To evaluate the efficacy of a community- based,
pharmacist-directed diabetes management program
among managed care organization enrolees using Na-
tional Committee for Quality Assurance (NCQA)–Health-
care Effectiveness Data and Information Set (HEDIS)
performance measures.
Primary:
HbA1c (< 7.0%), blood pressure (< 130/80 mmHg), and
LDL cholesterol (< 100 mg/dL).
A composite research outcome of success was created by
determining whether a participant achieved two of the





n = 179; IG (n = 87) and CG
(n = 92)
To evaluate the effectiveness of a community pharmacist
intervention (CPI) compared with usual care in
improvement of adherence to antidepressants and
patient well-being in a population initiating pharmaco-
logical treatment following diagnosis of depression.
Primary:
Adherence to antidepressants, clinical severity of





n = 395; IG (n = 207) and CG
(n = 188)
To evaluate a community pharmacist intervention to
improve adherence with antihypertensive medicines with
a view to improving blood pressure (BP) control.
Primary:
Change in proportion self-reporting medication adher-
ence (validated questionnaire).
Secondary:
BP changes and the proportion of self-reporting adher-





n = 734; IG (n = 371), CG (n =
363)
To test the effectiveness of a pharmaceutical care
programme in patients with Chronic Obstructive
Pulmonary Disease (COPD) in the community pharmacist
educational intervention.
Primary:
Improvement of the inhalation technique, and
medication adherence,
Secondary:
Reduction of Dyspnoea, severe exacerbations and
emergency visits or hospitalization.
Improvement of generic health status (quality of life) and





To study the impact of pharmacist prescribing on blood
pressure (BP) control in community-dwelling patients.
Primary:
Difference in change of systolic BP from baseline to 6
months between IG and CG.
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HbA1c [67, 70], CV risk [67], blood pressure [67, 69, 70,
72, 74], tobacco use [67], HDL [69] and LDL-cholesterol
[67]. Additionally, eight papers showed a statistically sig-
nificant improvement in process indicators of PPSs ef-
fectiveness, such as the inhaler technique [51, 73],
adherence [51, 68, 71–73] or resolution of drug related
problems (DRPs) [69, 75, 76]. MTM statistically de-
creased hospitalizations, bed-bound episodes and emer-
gency room visits [67, 71, 73, 74, 76].
Humanistic outcomes
Three out of the five papers [51, 68, 71, 73, 75] measur-
ing humanistic outcomes reported statistically significant
improvements in Health-Related Quality of Life (HR-
QoL) through the provision of Dispensing/ Adherence
[71] and MTM services [51, 75]. In these three papers,
HR-QoL was the primary outcome.
Economic outcomes
None of the papers involved any cost-effectiveness ana-
lysis. NMS [68] didn’t show a statistically significant re-
duction in National Health Service (NHS) costs.
Discussion
Stakeholders need pragmatic studies with high methodo-
logical quality to make evidenced based decisions on
which services to fund. To the best of our knowledge,
our paper is the first systematic review that evaluates
evidence from pragmatic RCTs of the effectiveness of
PPSs in the community pharmacy setting. One of the
main strengths of this review is the use of the PRECIS-2
tool, which allowed the characterization of the level of
pragmatism of the study designs. The PRECIS-2 tool
had previously shown good reliability with modest dis-
criminatory validity [60, 65]. Currently there are few
pragmatic papers on PPSs and researchers should make
wider use of this tool when designing their trials in an
attempt to provide practice-based data on specific PPSs.
Setting was one of the highest scored domains within
the studies, reflecting the ease of accessibility of commu-
nity pharmacies to implement PPSs. The second most
scored domain was the manner in which primary out-
comes were assessed. Most of the studies used ITT
which reinforced the external validity of their
conclusions.
In contrast, the low score obtained in domains related
to organisation criteria, recruitment and flexibility (ad-
herence) suggests a need to implement strategies that
enhance pharmacist training such as accreditation pro-
cesses, training in communication skills and teaching of
pragmatic methodologies [78–81]. According to our as-
sessment, studies with the highest score of pragmatism
were carried out in UK [68], Canada [74], Netherlands
[75] and US [76], countries coinciding with those de-
scribed by Mossialos et al. [2], as the most advanced
PPSs providers. Probably these countries provide a more
favorable environment for patient recruitment and PPSs
implementation, with experience in service accreditation
and remuneration.
Our findings reinforce previous conclusions on the ef-
fectiveness of PPSs [30, 82]. There was evidence (nine
out of the 12 pragmatic RCT) that supports PPSs clinical
effectiveness, specifically for prescribing interventions
and MTM services. These two services achieved statisti-
cally significant improvements in a variety of intermedi-
ate clinical outcomes such as blood pressure, pulmonary
Table 1 Description of key general characteristics of included papers (Continued)
Author / PPS/Country/
Publication year / Duration/
Number of patients
Objectives Outcome indicators
n = 248; IG (n = 181), CG (n =
67)
Secondary:
Change in diastolic BP. Number of: patients at their target
BP after 6 months, new antihypertensive medication, dose





n = 629; IG (n = 315) and CG
(n = 314)
To investigate the effect of a patient -centred CMR,
focused on personal goals, on health-related quality of
life (HR-QoL), and on number of health problems.
Primary:
HR-QoL (assessed with EuroQoL [EQ]-5D-5L and EQ-Visual
Analogue Scale [VAS])
Number of health problems, after 3 and 6months.
Secondary:
Number of: long-term medications, prescribed drugs
added and ceased. Severity of complaints measured with




n = 961; IG (n = 475) and CG
(n = 486)
To evaluate the effectiveness of a telephonic MTM service





The effect of hospitalization while adjusting for patients’
baseline risk. Number of medications taken daily. DRP
identified. Pharmacist’s recommendations. Physician’s
response.
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Table 2 Description of the interventions and detailed clinical, economic or humanistic primary outcomes of papers included
Author
PPS




Assessment of patient’s therapies and laboratory results, individualized CV
risk assessment, adjustment of treatment regimen, prescribing and
ordering laboratory tests to meet treatment targets, and self-report of ad-
verse events. Regular communication after each contact with the patients
and regular follow-up visits every 4 weeks for 3 months.
Improvement of: CV risk (absolute reduction 5.38%;
95%CI, 4.24–6.52; P < 0.001), (HbA1c (0.9%; 95%CI,
0.70–1.10; P < 0.001), systolic blood pressure (8.6
mmHg; 95%CI, 6.70–10.40; P < 0.001), diastolic blood
pressure (2.7 mmHg; 95%CI, 1.30–4.10; P < 0.001), LDL-
cholesterol, (0.2 mmol/L; 95%CI, 0.10–0.30; P = 0.004)
and Tobacco use (24.2% P < 0.001).
[51] Armour
DSM/MTM
Brief health education tips. Inhalation technical instruction.
Letter written to the doctor for the action plan. Asthma control and
spirometry performed at every visit measured using questionnaires and
spirometers.
Improvement of: percentage of patients achieving a
good/fair control in both groups 4-visit service: from
21 to 59%; 3-visit service: from 29 to 61% (mean = 0.57
for the three-visit group, 0.56 for the four-visit group,
P < .001). Improvement of the health-related quality of
life (Three visit 4.13 ± 1.41 to 3.39 ± 1.19; P < .001- ver-
sus Four-visit 4.45 ± 1.49 to 3.57 ± 1.48; P < .001). No
significant differences of asthma control between pa-





Pharmacist – led behavioural counselling combined with nicotine
replacement therapy (NRT). 1 (Group B) to 3 (Group A) face-to-face sessions
for behaviour change to quit smoking. On-line control surveys at 7 days,
and 5 and 12 weeks. Phone calls to those who did not attend the visits or
respond.
There were statistically significant differences between
each of the two groups receiving the service and the
group of patients that only received NTR by mail
(control group) 3-session service (× 2 = 217.30, P <
0.001; ITT: × 2 = 149.60, P < 0.001); 1-session service (×
2 = 93.90, P < 0.001; ITT: × 2 = 19.00, P < 0.001).
[68] Elliot
NMS
Pharmacist and GP service offering to the patient. The pharmacist asks
about adherence and medicines. One-to-one consultation 7–14 days after
the presentation of the prescription with a ‘follow-up’ of 14–21 days via
telephone.
Improvement of the percentage of adherent patients
1.67 (95%CI, 1.06–2.62; P = 0.027). Non-significant re-
ductions of health system costs (£21; 95%CI, £59 -
£150; P = 0.1281).
[69] Geurts
MTM
Pharmaceutical care Process (PCP) in cooperation between patient’s
pharmacist and GP, and agreed to by the patient: (1) assessment of
potential DRPs and pharmaceutical care issues (PCIs), (2) proposal of
interventions to reach treatment goals, and (3) implementation of the
interventions. Two measurements were performed, (t = 0) at the
beginning and (t = 1) after 1-year follow up.
Decrease of diastolic BP (95%CI, 79.80–76.80 mmHg;
P = 0.008) and increase of HDL-cholesterol: IG (IG:
95%CI, 1.29–1.37 mmol/L; P = 0.021; IG patients not re-
ceiving the whole service: 95%CI, 1.26–1.37 mmol/L;
P = 0.039); and GC: (95%CI, 1.30–1.36 mmol/L; P =
0.074). Non-significant decrease of LDL-cholesterol: IG
(IG: 95%CI, 2.72–2.63 mmol/L; P = 0.337; IG patients not
receiving the whole service: 95%CI, 2.98–2.67 mmol/L;




1-h face to face interview on a monthly basis (IG) and 30 min face to face
interview at 3- month intervals (CG).
IG: 1) Provision of written patient education materials. 2) Diabetes
education, coaching on self-management skills and medication adherence.
3) Assessment of medications and DRP. 4) Contact with GP via fax or tele-
phone to recommend treatment adjustments.
Improvement of the percentage of patients achieving
the control of their health problem: HbA1c (IG: 46.70%
vs. CG: 9.10%, P < 0.002), blood pressure (IG: 53.30% vs.
CG: 22.70%, P < 0.020). Non-statistically significant
higher percentage of patients achieving the LDL target






First visit: educational intervention centred on improving patients’
knowledge of antidepressants and awareness of the importance of
adherence and quality of life. Subsequent visits: short review of some
points covered in the first visit and checking of patient progress.
Improvement of the health-related quality of life (0.25
vs. 0.14) - effect size 0.31 vs 0.33 -. No statistically sig-





Home BP monitor. Training on BP self-monitoring (3–6-month follow-ups).
Motivational interviewing and education to medication adherence. Medica-
tion use review. Referral to a GP
Prescription refill reminders.
Improvement of the proportion of adherent patients
although there were not significant differences
between groups (57.2 to 63.6% CG vs 60.0 to 73.5% IG,
P = 0.23). Reduction of systolic BP was significantly
greater in the IG (7.2 mmHg 95%CI 1.6 12.8 mmHg;
P = 0.001). Reductions in BP of 10.00mmHg (IG) vs.
4.60 mmHg (CG); P = 0.050. Improvement of
percentage of non-adherent patients becoming adher-
ent 22.60% (95%CI, 5.10–40.00%) in the IG compared




Educational intervention (two sessions of 15–25min).
Electronically recorded medication, inhalation technique and
questionnaires about behavioural issues, etc.
Letter to the patient’s GP.
Significantly lower estimated annual severe
exacerbation rate in the IG compared with the CG
(0.27 (IG) vs. 0.61 (IC): RR = 0.45; 95%CI, 0.25–0.80; P <
0.007). Also, significantly 72% lower estimated annual
hospitalization rate in IG vs CG (0.10 vs. 0.40; RR = 0.28;
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exacerbations, HbA1c, CV risk, tobacco use, HDL and
LDL- cholesterol. Other type of services (Dispensing
/Adherence and NMS) did not report clinical effective-
ness. The inherent methodologic components of the ser-
vices, as well as other factors such as fidelity and
duration of the intervention, may be related to
favourable clinical outcomes. In Independent prescribing
and MTM services, pharmacists assess patient clinical
outcomes and develop interventions specifically tailored
to individual patient’s health status. In contrast, pharma-
cists providing Dispensing/Adherence and NMS services
focus their interventions predominantly on improving
the medication use process (inhaler technique, DRP).
The two studies with the highest pragmatic scores, one
evaluating a telephonic MTM service and the other asses-
sing the NMS, did not demonstrate any positive results on
hospitalizations nor medication adherence. This may be
due, or related to, the short duration of the studies (3
months and 10 weeks respectively) or to the components
of the service (i.g. telephonic follow-up). The additional
components or factors that may make telephonic MTM
or follow-up effective are unknown [83, 84].
There were three pragmatic studies supporting the ef-
fectiveness of PPSs (asthma DSM, Dispensing/Adher-
ence and MTM) on humanistic indicators (HR-QoL)
[51, 71, 75]. The studies that achieved statistically signifi-
cant improvements had follow-up visits and assessed the
effect at 6 months. These two components had been
previously reported as critical in achieving a humanistic
impact [34, 42, 82]. Therefore, studies measuring hu-
manistic indicators should consider longer durations and
follow-up periods.
Although there are many systematic reviews of PPSs
cost-effectiveness, these are undertaken in explanatory
RCTs [35, 36, 85]. In our review none of the papers ful-
filling our selection criteria for pragmatism assessed
cost-effectiveness. Three articles [68, 73, 76] reported
other economic indicators but in none of these there
was any significant statistical difference between groups.
The importance to stakeholders of cost-effectiveness
studies should not be underestimated since the sustain-
ability of services might be dependent on delivering
costs savings or cost-effectiveness to the healthcare
system.
Two key methodological quality aspects should be
considered when designing future pragmatic research.
We found only one study that blinded outcome assess-
ment, which may be considered as a potential bias that
could overestimate PPS effectiveness. Half of the studies
reported a risk of contamination, a very common threat
in the assessment of complex interventions. Thus cluster
designs controlling for potential risk of contamination
should be considered.
This review has several limitations due to the as-
sessment of pragmatism.The PRECIS-2 tool was ap-
plied after the screening process which allowed only
the consideration of papers meeting our inclusion cri-
teria. Since the PRECIS-2 tool suggests a continuum
between explanatory and pragmatic and no minimum
score is provided to classify a paper as pragmatic or
explanatory, the selected cut-off point (22.5 out of
45) could be questioned.The PRECIS-2 tool although
having good reliability has been reported to have
modest discriminatort validity [60]. Another limitation
relates to the variability of the different PPSs type
and their outcomes making it difficult to make com-
parisons between studies. Future studies should select
specific services to evaluate health outcomes using




PPSs components Health outcomes
95% CI, 0.12–0.64; P = 0.003) and a statistically
significant 73% lower rate of hospitalization days (0.87




Assessment of BP and cardiovascular risk. Education on arterial
hypertension. Prescribing of antihypertensive medications.
Laboratory monitoring and monthly follow-up visits for 6 months. Provision
of a wallet card for BP recording.
Greater reduction of systolic BP in the IG of 6.60 (1.90)
mmHg (P = 0.0006) and proportion of patients
achieving target BP 58% (IG) vs. 37% (CG), P = 0.020);
OR = 2.32 (95%CI, 1.17–4.15).
[75] Verdoorn
CMR/MTM
First visit: a patient interview for gathering information (health problems,
preferences, and all medications used). Identify potential DRPs and
propose recommendations to solve them. Subsequent visits: face-to-face
meeting with the patient’s GP to discuss all health-related goals and DRPs.
Two follow up appointments.
Improvement of the health-related quality of life: 3
months 1.70 points (95% CI, 0.47–2.90; P = 0.006) and




Home episodic skilled nursing care. Medication information was faxed
from nurse to the provider. Initial phone call by a pharmacy technician to
verify active drugs. Pharmacist-provided telephone MTM.
Follow - up pharmacist phone calls at 7-day and as needed for 30 day of
the 60-day home health care episodes.
Significant less probability of hospital readmission in
patients with a low baseline risk (adjusted OR: 3.79;
95%CI, 1.35–10.57; P = 0.01). No significant differences
in the 60- day probability of hospitalizations adjusted
OR: 1.26; (95%CI, 0.89–1.77; P = 0.190).
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pragmatic approaches, using the PRECIS-2 tool to de-
sign the study.
Conclusions
There is a need for pragmatic studies to evaluate eco-
nomic, clinical and humanistic outcomes of PPS as cur-
rently there is limited available evidence on the
effectiveness of these services.
Although few pragmatic RCT were found, most of
them showed evidence of clinical effectiveness. There is
scarce evidence of humanistic and economic outcomes.
The lack of an adequate number of pragmatic clinical
trials may be problematic to provide evidence of the sus-
tainability of the PPS. More focus and emphasis should
be given to increase the level of evidence of economic,
clinical and humanistic indicators from a pragmatic
perspective.
Researchers should consider the level of pragmatism
of their research design using the PRECIS-2 tool. This
would allow them to ensure the applicability of their
research.
Practical implications
There is limited evidence of PPS outcomes from prag-
matic studies. Therefore there is a need to undertake
further research on specific PPS, with patients under
normal practice conditions.
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del medicamento)
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